Evaluation of a drug-drug interaction alert structure through the retrospective analysis of statins-macrolides co-prescriptions

Basic and Clinical Pharmacology and Toxicology

Volumn 96, Issue 4, 2005, Pages 289-294

  Morera, Tomas ^a   Gervasini, Guillermo ^a   Carrillo, Juan Antonio ^a   Benitez, Julio ^a,b  

^a HOSPITAL INFANTA CRISTINA   (Spain)

^b UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CLARITHROMYCIN; CYTOCHROME P450 3A; ERYTHROMYCIN; MACROLIDE; MEVINOLIN; SIMVASTATIN; STATIN;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BIOTRANSFORMATION; DRUG EFFECT; DRUG INTERACTION; DRUG RELEASE; DRUG SURVEILLANCE PROGRAM; EVALUATION; FEMALE; GOOD CLINICAL PRACTICE; HIGH RISK POPULATION; HOSPITAL ADMISSION; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MYOPATHY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; RURAL HEALTH CARE; SIDE EFFECT; SPAIN; STRUCTURE ANALYSIS;

AGED; CORRESPONDENCE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFORMATION DISSEMINATION; MACROLIDES; MALE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 15944419566     PISSN: 17427835     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2005.pto960403.x     Document Type: Article

References (43)

1. Ahearn, M. D. & S. J. Kerr: General practitioners' perceptions of the pharmaceutical decision-support tools in their prescribing software. Med. J. Aust. 2003, 179, 34-37.
2. Alexandridis, G., G. A. Pappas & M. S. Elisaf: Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil. Amer. J. Med. 2000, 109, 261-262.
3. Amsden, G. W., O. Kuye & G. C. Wei: A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers. J. Clin. Pharmacol. 2002, 42, 444-449.
4. Bates, D. W., J. M. Teich, J. Lee, D. Seger, G. J. Kuperman, N. Ma'Luf, D. Boyle & L. Leape: The impact of computerized physician order entry on medication error prevention. J. Amer. Med. Inform. Assoc. 1999, 6, 313-321.
5. Bjerrum, L., M. Andersen, G. Petersen & J. Kragstrup: Exposure to potential drug interactions in primary health care. Scand. J. Prim. Health Care 2003, 21, 153-158.
6. Bond, C., C. Matheson, S. Williams, P. Williams & P. Donnan: Repeat prescribing: a role for community pharmacists in controlling and monitoring repeat prescriptions. Brit. J. Gen. Pract. 2000, 50, 271-275.
7. Buajordet, I., J. Ebbesen, J. Erikssen, O. Brors & T. Hilberg: Fatal adverse drug events: the paradox of drug treatment. J. Intern. Med. 2001, 250, 327-341.
8. Cenedella, R. J.: Beware of combining erythromycin with a statin. J. Amer. Osteopath. Assoc. 2003, 103, 117.
9. Chu, P. H., W. J. Chen, C. W. Chiang & Y. S. Lee: Rhabdomyolysis, acute renal failure and hepatopathy induced by lovastatin monotherapy. Jap. Heart J. 1997, 38, 541-545.
10. Coste, J. & A. Venot: An epidemiologic approach to drug prescribing quality assessment: a study in primary care practice in France. Med. Care 1999, 37, 1294-1307.
11. Egger, S. S., J. Drewe & R. G. Schlienger: Potential drug-drug interactions in the medication of medical patients at hospital discharge. Eur. J. Clin. Pharmacol. 2003, 58, 773-778.
12. Farmer, J. A.: Learning from the cerivastatin experience. Lancet 2001, 358, 1383-1385.
13. Fernando, B., B. S. Savelyich, A. J. Avery, A. Sheikh, M. Bainbridge, P. Horsfield & S. Teasdale: Prescribing safety features of general practice computer systems: evaluation using simulated test cases. Brit. Med. J. 2004, 328, 1171-1172.
14. Ferner, R. E.: Computer aided prescribing leaves holes in the safety net. Brit. Med. J. 2004, 328, 1172-1173.
15. Gemici, G., A. Toprak & A. Oktay: Rhabdomyolysis due to cerivastatin monotherapy. Amer. J. Med. 2001, 110, 742.
16. Glassman, P. A., B. Simon, P. Belperio & A. Lanto: Improving recognition of drug interactions: benefits and barriers to using automated drug alerts. Med. Care 2002, 40, 1161-1171.
17. Guedon-Moreau, L., D. Ducrocq, M. F. Duc, Y. Quieureux, C. L'Hote, J. Deligne & J. Caron: Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999. Eur. J. Clin. Pharmacol. 2003, 59, 689-695.
18. Halkin, H., I. Katzir, I. Kurman, J. Jan & B. B. Malkin: Preventing drug interactions by online prescription screening in community pharmacies and medical practices. Clin. Pharmacol. Therap. 2001, 69, 260-265.
19. Hamilton, R. A., L. L. Briceland & M. H. Andritz: Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population. Pharmacotherapy 1998, 18, 1112-1120.
20. Havens-Verkler, J. & A. M. Lewis: A 73-year-old woman with rhabdomyolysis induced by simvastatin (Zocor). J. Emerg. Nurs. 2004, 30, 9-11.
21. Heerey, A., M. Barry, M. Ryan & A. Kelly: The potential for drug interactions with statin therapy in Ireland. Ir. J. Med. Sci. 2000, 169, 176-179.
22. Isaksen, S. F., J. Jonassen, D. C. Malone, S. J. Billups, B. L. Carter & C. D. Sintek: Estimating risk factors for patients with potential drug-related problems using electronic pharmacy data. IMPROVE investigators. Ann. Pharmacother. 1999, 33, 406-412.
23. Kahri, A. J., M. M. Valkonen, M. K. Vuoristo & P. J. Pentikainen: Rhabdomyolysis associated with concomitant use of simvastatin and clarithromycin. Ann. Pharmacother. 2004, 719.
24. Kantola, T, K. T. Kivistö & P. J. Neuvonen: Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin. Pharmacol. Therap. 1998, 64, 177-182.
25. Kohler, G. I., S. M. Bode-Boger, R. Busse, M. Hoopmann, T. Welte & R. H. Boger: Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int. J. Clin. Pharmacol. Therap. 2000, 38, 504-513.
26. Landesman, K. A., M. Stozek & N. J. Freeman: Rhabdomyolysis associated with the combined use of hydroxymethylglutaryl-coenzyme A reductase inhibitors with gemfibrozil and macrolide antibiotics. Conn. Med. 1999, 63, 455-457.
27. Lee, A. J. & D. S. Maddix: Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann. Pharmacother. 2001, 35, 26-31.
28. Magnus, D., S. Rodgers & A. J. Avery: GPs' views on computerized drug interaction alerts: questionnaire survey. J. Clin. Pharm. Therap. 2002, 27, 377-382.
29. Mah Ming, J. B. & M. J. Gill: Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV. AIDS Patient Care STDS 2003, 17, 207-210.
30. Malone, D. C., J. Abarca, P. D. Hansten, A. J. Grizzle, E. P. Armstrong, R. C. Van Bergen, B. S. Duncan-Edgar, S. L. Solomon & R. B. Lipton: Identification of serious drug-drug interactions: results of the partnership to prevent drug-drug interactions. J. Amer. Pharm. Assoc. (Wash. DC) 2004, 44, 142-151.
31. Modi, J. R. & M. S. Cratty: Fluvastatin-induced rhabdomyolysis. Ann. Pharmacotherap. 2002, 36, 1870-1874.
32. Morera, T, G. Gervasini, J. A. Carrillo & J. Benitez: Early detection of drug interactions utilizing a computerized drug prescription handling system-focus on cerivastatin-gemfibrozil. Eur. J. Clin. Pharmacol. 2004a, 59, 917-921.
33. Morera, T., G. Gervasini, J. A. Carrillo & J. Benitez: Using a computerized drug prescription screening system to trace drug interactions in an outpatient setting (July/August). Ann. Pharmacotherap. 2004b, 1301-1306.
34. Muck, W., K. Ochmann, G. Rohde, S. Unger & J. Kuhlmann: Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Eur. J. Clin. Pharmacol. 1998, 53, 469-473.
35. Omar, M. A. & J. P. Wilson: FDA adverse event reports on statin-associated rhabdomyolysis. Ann. Pharmacotherap. 2002, 36, 288-95.
36. Peng, C. C., P. A. Glassman, I. R. Marks, C. Fowler, B. Castiglione & C. B. Good: Retrospective drug utilization review: incidence of clinically relevant potential drug-drug interactions in a large ambulatory population. J. Manag. Care Pharm. 2003, 9, 513-522.
37. Petty, D.: Drugs and professional interactions: the modern day pharmacist. Heart 2003, 89 Suppl 2, 31-32.
38. Siedlik, P. H., S. C. Olson, B. B. Yang & R. H. Stern: Erythromycin coadministration increases plasma atorvastatin concentrations. J. Clin. Pharmacol. 1999, 39, 501-504.
39. Sipe, B. E., R. J. Jones & G. H. Bokhart: Rhabdomyolysis causing AV blockade due to possible atorvastatin, esomeprazole, and clarithromycin interaction. Ann. Pharmacotherap. 2003, 37, 808-811.
40. Takada, M., M. Demizu & M. Shibakawa: Physicians' prescribing attitudes to combined therapy with statins and fibrates. J. Clin. Pharm. Therap. 2003, 28, 445-450.
41. Takei, A. & S. Chiba: Rhabdomyolysis associated with pravastatin treatment for major depression. Psychiatry Clin. Neurosci. 1999, 53, 539.
42. Thompson, C. A.: Cerivastatin withdrawn from market. Amer. J. Health Syst. Pharm. 2001, 58, 1685.
43. Williams, D. & J. Feely: Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin. Pharmacokinet. 2002, 41, 343-370.